Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | IL2 | P60568 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 4/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 4/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.46 |
| ▸ | PRKAG3 | Q9UGI9 | 4/20 | 0.46 |
| ▸ | PRKAG2 | Q9UGJ0 | 4/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914175 | 0.86 | ALPL (0.50) | SMN1; SMN2ALPLPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL2761945 | 0.85 | KDM4E (0.49) | ALPLPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL2762047 | 0.84 | KDM4E (0.51) | FLT3PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL2001667 | 0.84 | KDM4E (0.58) | SMN1; SMN2SRD5A2KDM4EALDH1A1HPGD | |
| SCHEMBL2761942 | 0.83 | RHEB (0.56) | IDO1TDO2SRD5A2KDM4EALDH1A1 | |
| SCHEMBL2761769 | 0.83 | ALPL (0.52) | FLT3ALBIL2ALPLSRD5A2 | |
| SCHEMBL2761944 | 0.82 | TDO2 (0.50) | IDO1TDO2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL30071297 | 0.82 | RHEB (0.50) | FLT3IDO1TDO2ALPLSRD5A2 | |
| SCHEMBL20495021 | 0.82 | RHEB (0.50) | FLT3IDO1TDO2ALPLSRD5A2 | |
| SCHEMBL2761931 | 0.81 | KDM4E (0.46) | SRD5A2KDM4EALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | claimed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | claimed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | claimed |
| EP-1720859-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2006-11-15 | — | — | EP | claimed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | claimed |
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| EP-1720859-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | FLT3 225/4885SMN1; SMN2 4303/4885ALB 4641/4885 |
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | FLT3 240/4885SMN1; SMN2 4263/4885ALB 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.